HealthSonix' Research Study Shows Clinically Significant Pain Reduction With Osteoarthritis Patients
Posted on: Wednesday, 13 December 2006, 09:01 CST
HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) today announced the completion of an AquaSonix Therapy "Guelph" clinical research study.
HealthSonix in cooperation with the City of Guelph Recreation Department conducted the study. The study was designed to measure the pain reduction and effectiveness of AquaSonix Therapy with people suffering with the pain of osteoarthritis, who were also actively involved in recreational aqua fitness classes. The trial was conducted over an 8-week period. The course of therapy was 15 treatment sessions, taken two days per week. Each participant completed the FDA-validated WOMAC questionnaire, and SF36 Lifestyle Questionnaire, which were used to monitor individual response to the therapy. Participants recorded their pain, stiffness and physical function levels before starting the study and upon completion.
"I am very encouraged by the treatment outcomes from this pilot study," said Dr. David Venturi, Medical Director of HealthSonix. "69% percent of patients experienced a clinically significant reduction in pain. The average decrease in pain was 45%, and the range of improvement was between 33 and 67 percent. Additionally, 50% of patients recorded a reduction in stiffness and 38% showed an improvement in physical function."
"Almost all of the patients at one point stated they were sleeping better," added Jacqueline Harrison, Kinesiologist and study administrator. Actual study results, based on individual WOMAC responses, confirmed 72% of patients had a clinically significant improvement in their sleep pattern.
There were no adverse reactions recorded. Comprehensive study results will be available by mid-January and are to be published in medical journals in 2007.
The American College of Rheumatology (ACR) treatment guidelines for the overall management of osteoarthritis patients stipulates that exercise should be an integral part in any treatment program for people with osteoarthritis. This latest study provides the science to validate and demonstrate why AquaSonix Therapy is one of the best non-pharmacologic therapies available for reducing pain and overall management of osteoarthritis. It can be stated with confidence that AquaSonix Therapy can be used stand alone or be safely combined with pharmaceuticals for best results.
"We intend to conduct further multi-centre research studies to expand the clinical indications for AquaSonix Therapy. We are looking to quantify the therapeutic benefit when AquaSonix Therapy is administered in conjunction with some of the most widely prescribed pain reducing medications such as Celebrex or when combined with over the counter medicines such as Tylenol or Advil," added Dr. Venturi.
HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) is a publicly traded medical technology company. The Company's core offerings are based on proprietary, patent pending medical technologies that use sound pressure to administer sub-sensory micro vibration to the human body. The technology is effective in reducing pain of multiple musculoskeletal conditions, particularly arthritis.
More information regarding HealthSonix and its products and services can be found at: www.HealthSonix.com or by calling the company at 1-877-622-2121.
Note: A number of statements contained in this report are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.
Contact: Dieter D. Doederlein 1-877-622-2121 Contact via http://www.marketwire.com/mw/emailprcntct?id=1600A579C209622E
SOURCE: HealthSonix, Inc.
Source: MARKET WIRE
Related Articles
- Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
- Alkermes and Indevus Announce Positive Results From Phase 2a Clinical Study of ALKS 27 for the Treatment of COPD
- ViroPharma Initiates First of Two Phase 3 Studies of Maribavir in Transplant Patients
- Study Demonstrates Safety of Promising Investigational Treatment for Deadly Brain Cancer
- Radiation Therapy Services Reports First Quarter 2006 Financial Results
- Cleveland Clinic Study Demonstrates CardioDynamics' BioZ(R) Changes Patient Treatment 39% of Time
- Clofarabine European Study Confirms Efficacy in Pediatric Patients With Acute Lymphoblastic Leukemia; Study Update at American Society of Hematology
- Icagen Reports Results of Phase II Open Label Extension Study of ICA-17043 for the Treatment of Sickle Cell Anemia
- European Union's CHMP Adopts Positive Opinion For Shorter Course of PEGINTRON(R) and REBETOL(R) Combination Therapy For Certain Hepatitis C Patients With Genotype 1 and Low Viral Load
- Imipenem/Cilastatin Versus Piperacillin/Tazobactam Plus Amikacin for Empirical Therapy in Febrile Neutropenic Patients: Results of the COSTINE Study*
 |
 |
User Comments (0)
RSS Feeds